|
Product Report
|
The Future of Targeted Therapeutics: Key technologies, new therapy area applications
In recent years, the maximization of blockbuster revenues has been compromised by generic price erosion and a decline in new drug approvals. Large pharmaceutical companies are coming under pressure to explore new R&D strategies and implement more cost-effective sourcing methods for innovative new molecules.
|
|
Read more...
|
|
|
Product Report
|
Convergence of Biomarkers and Diagnostics: Therapy area analyses, key products and future trends
 In recent years, there have been concerted efforts to enhance the precision of disease diagnosis and monitoring as the hetrogeneity of conditions becomes increasingly understood. Targeting broad patient populations in a ‘one-pill-fits-all’ approach has begun to attract criticism, with the average efficacy of such drugs being estimated at 50% or less.
|
|
Read more...
|
|
|
Product Report
|
 Nosocomial Vaccines - Minefield or Goldmine?
As the reimbursement status for the cost of hospital-acquired infections is under pressure by payors, interest in preventing these complications at the outset is growing.Nosocomial vaccines offer one route of prevention. This report assesses the clinical pipeline candidates five key nosocomial pathogens and their potential market environment including target population size estimates.
|
|
Read more...
|
|
|
Product Report
|
Percutaneous Coronary Intervention - Adverse events with drug-eluting stents
While drug eluting stents have been successful in reducing the rate of restenosis following percutaneous coronary intervention, there have been safety scares over a new problem: “in-stent thrombosis”. Opinion leaders are divided over the gravity of this problem, but positive safety data are required to restore physician confidence in drug eluting stents.
|
|
Read more...
|
|
|
<< Start < Prev 21 22 23 24 25 26 27 Next > End >>
|
| Results 235 - 238 of 238 |
Farmavita.Net Journal 
